Novel prebiotic fiber
for cardiovascular support

Nutrient
supplementation.

Prebiotic fiber

Dietary fiber is the edible parts of plants or carbohydrates that are resistant to digestion and absorption in the human small intestine, with complete or partial fermentation in the large intestine. 20 to 30 g a day are recommended by the health authorities, in forms of food but this recommendation remains a hard-to-reach target.
Prebiotics are types of soluble fibers that serve as substrate for targeted beneficial bacteria of our microbiome.

Characterization of the active compounds

Rosiom® is a native chitin-glucan biopolymer from the cell wall of the mycelium of Aspergillus niger. Rosiom® combines in a 3D-structure, the nutritional benefits of β-glucan and chitin prebiotics, to modulate the gut microbiota and the production of postbiotics.

ACTIVE COMPOUNDS

Chitin: 30-60%
Glucan: 40-70%

Formulation

Recommended daily dosage: 4.5 g

15-year research program on Rosiom®

Rosiom® has been approved as Novel Food in Europe and has a self-affirmed GRAS status in the USA.

Rosiom®: targeted prebiotic effect for probiotic benefits

CLINICAL TRIAL 1

POPULATION
15 healthy men & women
Age: 21 ± 1 years old

LENGTH
21-day supplementation

INTAKES
4.5 g /day of Rosiom®
Fiber-controlled diet

Rosiom® modulates selectively the activity and composition of gut microbiota with a specific selection of positive bacteria (Roseburia spp), butyrate- and vaccenic acid-producer.

ROSEBURIA spp.
  • Key role in the digestion of complex sugars
  • Part of commensal bacteria producing short-chain fatty acids
  • Sufficient presence of Roseburia is characteristic of a healthy gut & modification in abundance may affect various metabolic pathways

Rosiom®: postbiotic activity through short- & long-chain fatty acids (SCFA & LCFA)

IMMUNE HEALTH SUPPORT

WOMEN
CARDIOVASCULAR HEALTH

Rosiom® - Immune health support

EX-VIVO STUDY

Ex vivo approach on a human-like model of gut immune system axis:  Caco-2 (epithelial cell line) / THP1 (macrophage cell line) co-culture.

Evaluation of the barrier function

The increase in the SCFA production is proven to reinforce epithelial thigh junctions: 
Rosiom® improves the physical barrier first-line of immune defense.

Evaluation of the barrier function

tnf

The increased release of postbiotics modulates the inflammatory response:

  • Pro- and anti-inflammation markers are rebalanced
  • The inflammatory sentinel CXCL-10 significantly decreases

Rosiom® reinforces the second and third steps of the innate immune response.

 

Rosiom® – Cardiovascular health support

CLINICAL TRIAL

Double-blind, randomized, placebo-controlled
Multicenter study

POPULATION
37 healthy women
Age: 52 ± 12 years old
LCL-c normal to borderline

LENGTH
6-week supplementation

INTAKES
4.5 g /day of Rosiom®

Improvement of cholesterol homeostasis

  • Reduced conditions for foam cell formation with lowered LDL-c/HDL-c ratio
  • Increased conditions for reverse cholesterol transport with lowered oxLDL-C/HDL-c ratio
  • Decreased conditions for atherogenic process
  • PRE-CLINICAL STUDY

    Golden Syrian hamster
    Food-induced early atherosclerosis – Fatty streaks
    12 weeks

    Prevention of aortic fatty streaks

    KEY OUTCOMES

    • Patented ingredient
    • Modulates selectively gut microbiota with a  specific selection of Roseburia spp, butyrate- and vaccenic acid-producer
    • Supports immune homeostasis
    • Improves women cardiovascular health
    • EU Novel Food Approval
    • Self-affirmed GRAS

    Applications

    Commercial name
    Rosiom®
    Composition
    Chitin-Glucan biopolymer from Aspergillus Niger
    ACTIVE COMPOUNDS

    Chitin: 30-60%
    Glucan: 40-70%

    APPLICATIONS

    Food, functional food, dietary supplements

    OTHERS

    Patented ingredient, vegetarian, no allergen, non-GMO, halal, kosher, gluten-free

    References

    1 – PMID: 32893709
    2 – PMID: 19222573
    3 – PMID: 17209019
    4 –  PMID: 25722654
    5 – PMID: 30915065

    6 – PMID: 24390544
    7 – PMID: 30939754
    8 – PMID: 32893709
    9 – PMID: 19154104

    These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
    Fill form to contact us
    Fill form to receive the brochure
    Disclaimer

    This website is intended to provide information about Fytexia’s ingredients, used in various dietary supplement products around the world. It is intended to provide information to food supplement professionals and is not designed for the general public. As Fytexia’s ingredients are being marketed in a large number of countries, it is the responsibility of each of our customers to ensure that the use of the ingredient and any claim made in the labeling or advertising of the ingredient comply with the applicable rules and regulations.